MARA Holdings
MARA
MicroStrategy
MSTR
Coinbase
COIN
Tesla
TSLA
Amazon
AMZN
US Stock MarketDetailed Quotes
COLL Collegium Pharmaceutical
- 33.350
- -0.110-0.33%
Close Jan 17 16:00 ET
- 33.350
- 0.0000.00%
Post 16:20 ET
1.08BMarket Cap14.25P/E (TTM)
33.730High32.913Low264.28KVolume33.500Open33.460Pre Close8.80MTurnover0.88%Turnover Ratio25.85P/E (Static)32.25MShares42.28752wk High4.59P/B1.00BFloat Cap28.39052wk Low--Dividend TTM30.08MShs Float42.287Historical High--Div YieldTTM2.44%Amplitude7.370Historical Low33.313Avg Price1Lot Size
About Collegium Pharmaceutical Company
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Company Profile
SymbolCOLL
Company NameCollegium Pharmaceutical
Listing DateMay 7, 2015
Issue Price12.00
Founded2002
CEOMr. Vikram Karnani
MarketNASDAQ
Employees197
Fiscal Year Ends12-31
Address100 Technology Center Drive,Suite 300
CityStoughton
ProvinceMassachusetts
CountryUnited States of America
Zip Code02072
Phone1-781-713-3699
Company Executives
- Name
- Position
- Salary
- Vikram Karnani
- Director, President and Chief Executive Officer
- --
- Scott Dreyer
- Executive Vice President and Chief Commercial Officer
- 2.61M
- Colleen Tupper
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 2.73M
- Shirley R. Kuhlmann
- Executive Vice President, General Counsel, Secretary and Chief Administrative Officer
- 2.87M
- Dr. Thomas B. Smith, M.D.
- Executive Vice President and Chief Medical Officer
- 2.04M
- Michael T. Heffernan, R.Ph.
- Chairman of the Board
- 330.61K
- Dr. John A. Fallon, M.D.
- Independent Director
- 289.61K
- Gwen A. Melincoff
- Independent Director
- 275.61K
- Gino Santini
- Lead Independent Director
- 322.61K
- Garen G. Bohlin
- Independent Director
- 299.61K
- Dr. John G. Freund,M.D.
- Independent Director
- 298.61K
- Dr. Rita Balice-Gordon, PhD
- Independent Director
- 275.61K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.